Leucettinib-21, a DYRK1A inhibitor drug candidate aiming at the correction of cognitive disorders in people with Down syndrome or Alzheimer’s disease (unset title)

actions - event

Workflow history

from state (1)	to state	comment	date
submitted	published		2023/09/27 14:03 UTC

Event #730798 - latest update on 2023/09/27, created on 2023/09/27